$GH

Talasaz AmirAli sold $39.3M of GH (indirect holdings)

Talasaz AmirAli (Co-Chief Executive Officer) sold 260,000 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $151.20 ($150.49–$153.00, $39.31M total) across 6 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Talasaz AmirAli
Published Jun 30, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider selling datapoint (size, price range, and post-transaction holdings). However, absent any new operational or regulatory development, it is more likely to influence short-term sentiment than valuation.

02

Market read

Traders may monitor for follow-through in sentiment/positioning, but the 10b5-1 framing reduces the bearish interpretability.

03

What to watch

The filing does not disclose why the shares were sold or whether other insiders/large holders acted similarly around the same window.

Relevance 6/10Novelty 6/10Timing: filed 2026-06-30 after-hours; reflects sales executed 2026-06-26 to 2026-06-29

Background

SEC Form 4 reports an insider transaction by Guardant Health co-CEO Talasaz AmirAli, including that it was executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health co-CEO Talasaz AmirAli sold ~$39.3M of GH via a 10b5-1 plan across 6 trades at ~$150.49–$153.00.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small versus broader tape/earnings catalysts.

Evidence & confidence

Form 4 provides primary transaction details and the plan is pre-arranged; without accompanying guidance, litigation, or operating news, the fundamental signal is weak.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical catalyst.

None indicated; US-listed biotech/healthcare sentiment only.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification/liquidity needs rather than bearish expectations.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider sale; co-CEO sold 260,000 shares worth ~$39.3M.

  • Talasaz AmirAli

    Co-Chief Executive Officer and director; executed open-market sales under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.